TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has issued an announcement.
IRLAB Therapeutics announced the acceptance of two abstracts for presentation at the AD/PD 2026 conference, highlighting their research on Parkinson’s disease. This participation is expected to enhance their scientific network and boost confidence in their drug development pipeline, potentially impacting their position in the industry.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK2.50 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Swedish company focused on discovering and developing transformative treatments for Parkinson’s disease. Originating from Nobel Laureate Prof Arvid Carlsson’s research, the company has a pipeline that includes Mesdopetam for levodopa-induced dyskinesias, Pirepemat for fall frequency in Parkinson’s, and IRL757 for apathy in neurodegenerative disorders. Their research is driven by a proprietary systems biology-based platform, and they are listed on Nasdaq Stockholm.
Average Trading Volume: 224,479
Technical Sentiment Signal: Sell
Current Market Cap: SEK201.3M
For a thorough assessment of IRLAB.A stock, go to TipRanks’ Stock Analysis page.